{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"16"}]}],"title":"PR interval >= 220 ms"},{"categories":[{"measurements":[{"groupId":"OG000","value":"12"}]}],"title":"QRS >= 120 ms"},{"categories":[{"measurements":[{"groupId":"OG000","value":"20"}]}],"title":"QTcF > 30 ms and <= 60 ms"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"QTcF > 60 ms"},{"categories":[{"measurements":[{"groupId":"OG000","value":"25"}]}],"title":"QTcB > 30 ms and <= 60 ms"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}],"title":"QTcB > 60 ms"},{"categories":[{"measurements":[{"groupId":"OG000","value":"3"}]}],"title":"Heart rate <= 50 bpm"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}],"title":"Heart rate >= 120 bpm"}],"denoms":[{"counts":[{"groupId":"OG000","value":"81"}],"units":"Participants"}],"description":"A 12-lead ECG was recorded after the participant has been in a supine position breathing quietly for 5 minutes. The ECG results was used to evaluate the heart rate, atrial ventricular conduction, PR interval, QRS, QTcF and QTcB. Number of participants with clinical significant abnormalities in ECG parameter reported here. Clinically Significance was decided by investigator.","groups":[{"description":"Participants with metastatic Merkel cell carcinoma (MCC) after failing first-line chemotherapy received Avelumab at a dose of 10 milligram per kilogram (mg/kg) as 1-hour intravenous infusion once every 2 weeks until therapeutic failure, significant clinical deterioration, unacceptable toxicity, or any criterion for withdrawal from the trial or investigational medicinal product occurs.","id":"OG000","title":"Part A: Avelumab"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Safety analysis set included all participants who received at least 1 dose of study treatment. Here \"Number of participants analyzed\" signifies those who were evaluable for this outcome measure.","reportingStatus":"POSTED","timeFrame":"Up to 325 weeks","title":"Part A: Number of Participants With Clinically Significant Abnormalities in Electrocardiogram (ECG)","type":"SECONDARY","unitOfMeasure":"Participants"}